Journal Article

A 12-Month–Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response

Anna P. Durbin, Beth D. Kirkpatrick, Kristen K. Pierce, Marya P. Carmolli, Cecilia M. Tibery, Palmtama L. Grier, Noreen Hynes, Kari Opert, Adrienne P. Jarvis, Beulah P. Sabundayo, Benjamin D. McElvany, Eli A. Sendra, Catherine J. Larsson, Matthew Jo, Janece M. Lovchik, Catherine J. Luke, Mary C. Walsh, Ellen A. Fraser, Kanta Subbarao and Stephen S. Whitehead

in The Journal of Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 214, issue 6, pages 832-835
Published in print September 2016 | ISSN: 0022-1899
Published online February 2016 | e-ISSN: 1537-6613 | DOI:

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology


Show Summary Details


The ideal dengue vaccine will provide protection against all serotypes of dengue virus and will be economical and uncomplicated in its administration. To determine the ability of a single dose of the live attenuated tetravalent dengue vaccine TV003 to induce a suitable neutralizing antibody response, a placebo-controlled clinical trial was performed in 48 healthy adults who received 2 doses of vaccine or placebo administered 12 months apart. Evaluation of safety, vaccine viremia, and neutralizing antibody response after each dose indicated that the first dose of vaccine was capable of preventing infection with the second dose, thus indicating that multiple doses are unnecessary.

Clinical Trials Registration. NCT01782300.

Keywords: dengue vaccine; live attenuated tetravalent; clinical trial

Journal Article.  2803 words. 

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology